In October 2023, Sanofi, a leading global pharmaceutical company, announced a major shift in its business strategy. This shift involved the separation of its consumer health division, a move set to be completed in 2024. Historically, Sanofi's consumer health division, which includes popular
Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing
October 2024 saw a surge in biotech investments, with notable contributions from companies across North America, Europe, and the Asia-Pacific regions. Major players like Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics secured substantial funding, reflecting the growing
Innovent Biologics Inc. (1801.HK), a significant player in the Chinese biopharmaceutical sector, recently faced harsh backlash from investors due to a misstep in its strategy. The company aimed to strengthen its executives' dedication to its international unit, Fortvita, by selling a stake to the
ApiJect Systems Corp., a public-benefit medical technology company, has recently secured an initial grant of $425,000 from the Bill & Melinda Gates Foundation. This significant funding aims to support the design and development of low-cost Prefilled ApiJect Injectors to make single-use prefilled
Recent developments in the pharmaceutical industry underscore the volatile nature of advancements and market dynamics affecting prominent companies. The latest updates reveal a mix of struggles and achievements that highlight how pharmaceutical giants are navigating the complexities of drug
